Therapieoptionen beim Multiplen Myelom

Das Multiple Myelom war schon in den vergangenen Jahren eines der dynamischsten Felder der gesamten Onkologie. Und auf dem EHA 2019 und dem ASH 2019 wurden wieder spannende Studien vorgestellt. Dieser Beitrag fasst den aktuellen Stand zusammen.

Publikationsverlauf

Artikel online veröffentlicht:
11. Mai 2020

• Literatur

• 1 www.gekid.de/Atlas/CurrentVersion/atlas.html
• 2 www.statistik.at/web_de/statistiken/gesundheit/krebserkrankungen/brust/index.html
• 3 www.nicer.org/en/statistics-atlas/cancer-incidence/
• 4 Onkopedia-Leitlinie Multiples Myelom. www.onkopedia.com/de/onkopedia/guidelines/multiples-myelom
• 5 Rajkumar SV, Dimopoulos MA, Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538-e548
• 6 Kyle RA, Larson DR, Therneau TM. et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 2018; 378: 241-249
• 7 Palumbo A, Avet-Loiseau H, Oliva S. et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 2015; 33: 2863-2869
• 8 Kastritis E, Terpos E, Roussou M. et al. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica 2017; 102: 593-599
• 9 Engelhardt M, Dold SM, Ihorst G. et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica 2016; 101: 1110-1119
• 10 Chng WJ, Chung TH, Kumar S. et al. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia 2016; 30: 1071-1078
• 11 Munshi NC, Avet-Loiseau H, Rawstron AC. et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma. A meta-analysis. JAMA Oncol 2017; 3: 28-35
• 12 Kortüm M, Bittrich M, Schreder M. Moderne Diagnostik des multiplen Myeloms. Onkologe 2018; 24: 609-612
• 13 Kumar S, Paiva B, Anderson KC. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328-e346
• 14 Roshal M, Flores-Montero JA, Gao Q. et al. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Adv 2017; 1: 728-732
• 15 Attal M, Lauwers-Cances V, Hulin C. et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med 2017; 376: 1311-1320
• 16 Cavo M, Tacchetti P, Patriarca F. et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075-2085
• 17 Greipp PR, San Miguel J, Durie BG. et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420
• 18 Costa LJ. et al Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based Dara-Krd consolidation in patients with newly diagnosed multiple myeloma (NDMM). ASH 61st Annual Meeting and Exposition, Orlando, FL 2019; Abstract 860
• 19 Moreau P, Attal M, Hulin C. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019; 394: 29-38
• 20 Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood 2017; 130: 963-973
• 21 Usmani SZ. et al Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma: Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688). ASH 2019; Abstract #LBA-6
• 22 Attal M, Richardson PG, Rajkumar SV. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019; 394: 2096-2107
• 23 Schjesvold F. et al. ASH 61st Annual Meeting and Exposition, Orlando, Abstract 189.
• 24 Kumar S, Harrison S, Cavo M. et al A phase 3 study of Venetoclax or placebo in combination with Bortezomib and Dexamethasone in patients with relapsed/refractory multiple myeloma. EHA 2019; Abstract LBA 2601
• 25 Richardson PG, Oriol A, Larocca A. et al. HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety. Clin Lymph Myelom Leukem 2019; 19 (Suppl. 01) S329-S330
• 26 Mailankody S, Htut M, Lee KP. et al JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE). Oral presentation at: American Society of Hematology 60th Annual Meeting & Exposition; December 1–4, 2018; San Diego, California. Abstract 957
• 27 Madduri D, Usmani D, Jagannath S. et al Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM). ASH 61st Annual Meeting and Exposition, Orlando, FL 2019; Abstract 577